Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2025)
Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -99.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4,309.91% |
| Dec 31, 2024 | 102.74% |
| Sep 30, 2024 | 98.94% |
| Jun 30, 2024 | 90.70% |
| Mar 31, 2024 | 93.11% |
| Dec 31, 2023 | -146.58% |
| Sep 30, 2023 | 29.12% |
| Jun 30, 2023 | -39.62% |
| Mar 31, 2023 | -1.72% |
| Dec 31, 2022 | -30.08% |
| Sep 30, 2022 | -120.69% |
| Jun 30, 2022 | -1,374.79% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | 394.18% |
| Sep 30, 2021 | -21,532.84% |
| Jun 30, 2021 | 108.03% |
| Mar 31, 2021 | 42.00% |
| Dec 31, 2020 | -326.31% |
| Sep 30, 2020 | 99.75% |
| Jun 30, 2020 | 29.91% |